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The host range of African trypanosomes is influenced by innate protective molecules in the blood of primates.
A subfraction of human high-density lipoprotein (HDL) containing apolipoprotein A-I, apolipoprotein L-I, and
haptoglobin-related protein is toxic to Trypanosoma brucei brucei but not the human sleeping sickness parasite
Trypanosoma brucei rhodesiense. It is thought that T. b. rhodesiense evolved from a T. b. brucei-like ancestor and
expresses a defense protein that ablates the antitrypanosomal activity of human HDL. To directly investigate
this possibility, we developed an in vitro selection to generate human HDL-resistant T. b. brucei. Here we show
that conversion of T. b. brucei from human HDL sensitive to resistant correlates with changes in the expression
of the variant surface glycoprotein (VSG) and abolished uptake of the cytotoxic human HDLs. Complete
transcriptome analysis of the HDL-susceptible and -resistant trypanosomes confirmed that VSG switching had
occurred but failed to reveal the expression of other genes specifically associated with human HDL resistance,
including the serum resistance-associated gene (SRA) of T. b. rhodesiense. In addition, we found that while the
original active expression site was still utilized, expression of three expression site-associated genes (ESAG)
was altered in the HDL-resistant trypanosomes. These findings demonstrate that resistance to human HDLs
can be acquired by T. b. brucei.
Three subspecies of Trypanosoma brucei have been de-
scribed previously based on host range and course of infection
(17, 18, 19, 26). Trypanosoma brucei brucei causes nagana in
cattle and livestock in sub-Saharan Africa, Trypanosoma brucei
rhodesiense causes acute human African sleeping sickness in
East Africa, and Trypanosoma brucei gambiense causes chronic
human African sleeping sickness in West Africa. The phyloge-
netic relationship of these three organisms has been difficult to
resolve, particularly for T. b. brucei and T. b. rhodesiense, which
are morphologically indistinguishable and infect the same wild-
animal hosts (17).
A distinguishing feature of T. b. brucei is its inability to infect
humans. This innate protection is provided by trypanolytic
activity found in normal human blood and also in the blood of
most apes and Old World monkeys (24, 31, 46, 56). The try-
panosome lytic factor (TLF) is a minor subfraction of hetero-
geneous human high-density lipoprotein (HDL) particles con-
taining apoliprotein A-I (apoA-I), apoliprotein A-II (apoA-II),
apolipoprotein L-I (apoL-I), and haptoglobin-related protein
(Hpr) (23, 29, 38, 45, 48, 49, 50, 51, 52, 57, 59, 60, 64, 65, 69).
The mechanism of TLF killing of T. b. brucei has been contro-
versial. Initially, Hpr was suggested to be the active component
in TLF, based on the evolution of the Hpr gene during primate
evolution, the correlation of the trypanolytic activity in primate
sera, and the presence of the Hpr gene in T. b. brucei-resistant
animals (33, 56, 59). More recently, highly purified, recombi-
nant apoL-I has been shown to have trypanosome-killing ac-
tivity (45, 69). It now appears that Hpr and apoL-I both have
trypanosome-killing activity and that the assembly of these
proteins into the same HDL particle is synergistic, resulting
in a naturally occurring supercomplex with enhanced activity
compared with that of HDLs lacking either Hpr or apoL-I
(57). The biochemical mechanism of TLF killing of T. b. brucei
also continues to be debated (4, 36, 37, 45). However, there is
good agreement that trypanosome killing by TLF follows a
pathway beginning with high-affinity binding to a receptor in
the flagellar pocket of the trypanosome, followed by endocy-
tosis and localization to the lysosome. Within the acidic lyso-
some, TLF is activated and causes cell death. Inhibition of TLF
trafficking to the lysosome or neutralization of the lysosomal
pH abolishes TLF-mediated killing of T. b. brucei (13, 20, 21,
28, 30, 41, 49, 58, 70).
The discovery of a human serum resistance-associated gene
(SRA) in T. b. rhodesiense, but not in T. b. brucei, provided a
molecular explanation for human infectivity by these parasites
(9, 10, 11). Several experiments have shown a correlation be-
tween the expression of the SRA gene and resistance to human
serum (11, 35), and transfection of this gene into T. b. brucei
conferred resistance to human serum and TLF (41, 74). In
addition, the SRA gene has proven to be a reliable marker for
T. b. rhodesiense in epidemiological studies throughout East
Africa (16, 18, 39, 47, 72, 73).
The expression of the SRA gene is unstable when T. b.
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rhodesiense is maintained outside the human host. Repeated
passage of human serum-resistant T. b. rhodesiense in mice
results in a loss of SRA expression and a corresponding loss of
serum resistance. When these human serum-susceptible lines
are placed under TLF selection, some cells revert to the TLF
resistance phenotype by reactivation of SRA gene expression
(22, 35, 74).
Although differing in susceptibility to TLF, all three subspe-
cies of T. brucei evade the host adaptive immune system by
periodically changing the expressed variant surface glycopro-
tein (VSG) (7, 12, 32, 68). The expressed VSG gene lies at the
end of a telomere in one of 20 polycistronically transcribed
expression sites (ES). These expression sites also contain genes
known as expression site-associated genes (ESAGs) that code
for bloodstream-specific proteins, including the transferrin re-
ceptor (Tf-R). It has been postulated that genes in ES may be
grouped and arranged to help the trypanosome survive in dif-
ferent hosts and environments (1, 44). In T. b. rhodesiense, SRA
is an expression site-associated gene and shares some features
with VSGs (74). Because of the similarities between T. b.
rhodesiense and T. b. brucei, the origins of human serum resis-
tance have been debated. However, it is generally thought that
the SRA gene originated from a VSG gene in an ancestral,
human serum-sensitive trypanosome (8, 11).
We wanted to determine whether repeated exposure of T. b.
brucei to human HDLs would generate resistance to human
HDL killing without the presence of the SRA gene. Several
HDL-resistant populations emerged during the selection pe-
riod, and the molecular and cellular characteristics of one of
these trypanosome populations are reported here. Endocytosis
of TLF did not occur in these trypanosomes, and they could be
cultivated in media containing high concentrations of human
HDL or normal human serum. Surprisingly, the selection for
human HDL resistance correlated with a change in the ex-
pressed VSG and recombination events in the 221 expression
site (221ES), leading to changes in the expression of ESAG1,
-2, and -3. These in vitro-generated lines may provide impor-
tant insight into the mechanism and evolution of human infec-
tivity by African trypanosomes.
MATERIALS AND METHODS
Trypanosome strains and in vitro selection. Bloodstream stages of the T. b.
brucei Lister strain 427 (MiTat 1.2), expressing VSG221, were used in these
studies. Cells were cultured in HMI-9 medium with the addition of heat-inacti-
vated fetal bovine serum (FBS) (10%) and Serum Plus (10%) (JRH Biosciences,
Kansas). T. b. brucei 427-221 is an antigenically stable line and contains a single
copy of the VSG221 gene within the 221ES (3).
At a cell density of approximately 1  106 cells/ml, T. b. brucei 427-221 cells
were exposed to various amounts of human HDLs for 24 h in a six-well plate (see
Table 1 for amounts). Surviving trypanosomes were counted using a hemacy-
tometer and then diluted into fresh HMI-9 medium and allowed to recover for
5 to 14 days. Once the cells had grown to a density of approximately 1  106
cells/ml, they were again incubated with human HDLs. Each round of selection
was performed with increasing concentrations of human HDLs, and freezer
stocks were prepared for each surviving population. Over 9 months we conducted
eight rounds of human HDL selection, resulting in a population of T. b. brucei
that survived incubation with 800 l of human HDLs (160 lytic U).
Purification of human HDLs and trypanosome lysis assays. Normal human
serum was obtained from a healthy donor and total serum HDLs prepared by
sequential flotation on sodium bromide gradients (1.063 and 1.26 g/ml) as de-
scribed previously (23). The HDL samples were stored in small aliquots at70°C
to minimize the number of freeze-thaw cycles. At the beginning of the study, the
specific activity of the purified HDL was determined to be 1 trypanolytic unit (1
U) per 0.1 l. The concentration of HDL was approximately 2.35 g per l. For
the in vitro lysis assays, a unit is defined as the amount of HDL needed to lyse
50% of the trypanosomes during a 2-h incubation at 37°C. The lysis reactions
contained 1  107 bloodstream-form trypanosomes in 300 l of F12 media
containing 15% heat-inactivated FBS and 1% glucose, buffered with 25 mM
HEPES (pH 7.5). After 9 months, the activity of this human HDL preparation
decreased to 1 U per 5 l. The naming of the various HDL-resistant populations
indicates the maximum amount of HDL the cells survived during selection. For
example, T. b. brucei 427-800 was able to survive overnight in a total culture
volume of 3 ml containing 800 l of HDLs. Since the specific activity of the HDL
decreased over the course of the selection experiment, cell populations were
retested for TLF susceptibility at the end of the study.
To verify that the observed resistance to human HDL was specific to TLF,
several cell lines (427-221, 427-12, 427-20, 427-60, and 427-800) were retested for
susceptibility to both highly purified TLF and intact human serum. TLF was
purified from total human HDLs by immunoaffinity chromatography using an
Hpr-specific monoclonal antibody (13). The anti-Hpr affinity column was pre-
pared using Affi-gel 10 (Bio-Rad) according to the manufacturer’s recommen-
dations. Total human HDL (density, 1.063 to 1.26 g/ml) was purified by flotation
on sodium bromide, dialyzed against phosphate-buffered saline (PBS) containing
3 mM EDTA, pH 7.5, and concentrated to 0.4 mg/ml with an Amicon filtration
concentrator (Amicon no. 4306). Hpr-containing HDLs were bound to the anti-
Hpr column, washed with PBS containing 3 mM EDTA, pH 7.5, and eluted using
100 mM glycine at pH 2.0. Following elution, this highly purified preparation of
TLF was neutralized by the addition of 1 M Tris, pH 7.5. The Hpr-specific
monoclonal antibody reacts with human Hpr, whether free or in Hpr-containing
HDLs, but shows no cross-reactivity with other human serum proteins (57). This
TLF was used for all standard lysis assays presented.
SDS-polyacrylamide gel electrophoresis and Western blotting. For the anal-
ysis of total cell protein, trypanosomes were incubated in lysis buffer (100 mM
Tris, pH 8.0, 10 mM EDTA, 0.5% sodium dodecyl sulfate [SDS]), and an
equivalent of 3  106 cells per lane was run on 8% or 10% SDS-polyacrylamide
gels. Following electrophoresis, proteins were transferred to a nitrocellulose
filter membrane (0.45 m; Protran, Schleicher and Schuell, Dassel, Germany)
for 1.5 h at 60 V and probed for VSG221 by standard Western blotting methods.
Alexa labeling of TLF and immunofluorescence microscopy. Cultured try-
panosomes were collected by centrifugation at 2,500  g for 10 min at room
temperature. Cells were then resuspended in HMI-9 media at a density of 3 
107 cells/ml. TLF (100 g) was fluorescently labeled using an Alexa Fluor 488
protein labeling kit (Molecular Probes, California). Alexa-labeled TLF (6 g)
was added to 3  107 trypanosomes and then incubated at 37°C for 1.5 h. Cells
were then collected and washed three times with ice-cold PBS containing 1%
glucose. After the last wash, the cell pellet was resuspended in ice-cold PBS
containing 1% glucose at one-fourth the original volume of media. The cells were
smeared onto a glass slide and fixed with methanol. Once the slide was dry, it was
blocked with PBS containing 10% FBS for 1 h at room temperature. The slides
were incubated with primary antibodies, either a polyclonal antiserum against
VSG221 or a monoclonal antibody against lysosomal protein p67 (1:4,000 and
1:1,000 dilution, respectively), for 1 h at room temperature and washed with PBS
containing 1% FBS. Secondary antibodies were then added at a dilution of
1:1,000 and incubation continued at room temperature for 1 h. In the last 10 min
of the incubation, DAPI (4,6-diamidino-2-phenylindole) was added at a con-
centration of 2 g/ml to stain the nucleus and kinetoplast. Slides were washed in
PBS containing 1% FBS, Fluoromount G was added, and a coverslip was
mounted. The slides were viewed and images were captured using a Zeiss
Axiocam camera. Pictures were taken using automated gain as well as manual
gain times. To negate any difference due to image capture, the gain time for TLF
exposures was kept constant. To block acidification of the trypanosome lyso-
some, samples were pretreated with 50 M chloroquine for 30 min at 37°C prior
to TLF incubation. This treatment blocked TLF-mediated lysis and allowed
maximal accumulation of TLF in the lysosome (58).
Identification of the expressed VSGs and transferrin receptor. The expressed
VSGs and transferrin receptor (ESAG6 and ESAG7) were identified by cDNA
cloning of reverse transcriptase PCR (RT-PCR) products. A universal 3 VSG
primer (5-GGGTAACTTACGTGTTAAAATATATCAG-3) and a 5 spliced
leader RNA primer (5-CGCTATTATTAGAACAGTTTCTGTAC-3) were
used to amplify and clone the expressed VSG cDNA. ESAG6/7 primers (5-G
CGAATTCCCTTTACAAAATTGAGGATTC-3 and 5-GCTCTAGACAT
CACTGCATTTTTGCTTC-3) were used to amplify and clone the expressed
ESAG6/7 cDNA. Following reverse transcription and PCR, amplified bands
were excised from the gel, purified, and cloned into the TA vector for DNA
sequencing.
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RNA isolation, RT-PCR, probe labeling, and Northern blot analysis. Total
trypanosome RNA was isolated using Tripure isolation reagent (Roche, Mann-
heim, Germany), and RT-PCR was performed on 1 to 3 g by use of a Super-
script III first-strand synthesis system for RT-PCR (Invitrogen, Carlsbad, CA).
Primers for ESAG1 (5-AAGGACAGTGTGGGAGGATG-3 and 5-GAAAC
GGCTTTGGAGTGAAG-3), ESAG2 (5-CCCGATTGGGACACAATTAC-3
and 5-CATGTGAATCCCGCAGTATG-3), ESAG3 (5-TCATGCAACACAA
GGATGGT-3 and 5-AATAGGCTGTCCGGGAAAAT-3), and ESAG8 (5-
CCTTGAGGCTTTGTCTCTGG-3 and 5-CAAATTACGCAAATTCCCGA
C-3) were used to amplify the expressed ESAG from 427-221 and 427-800
trypanosomes. After RT-PCR, products were gel purified and cloned into the TA
vector for sequencing. For Northern blot analysis, 2.5 g total RNA was sepa-
rated on a 1% agarose formaldehyde gel and electroblotted at 15 V for 1 h and
then for an additional 2 h at 50 V onto a charged nylon membrane. The blot was
hybridized overnight with a digoxigenin-labeled probe at 40°C in Easy Hyb buffer
(Roche, Mannheim, Germany). Immunological detection of digoxigenin-labeled
probe by chemiluminescence was performed according to the manufacturer’s
instructions.
Radiolabeled probes were generated using a random primer labeling kit
(Stratagene, La Jolla, CA). The SRA probe was generated from the cloned T. b.
rhodesiense SRA gene (KETRI 2482) by using SRA-specific primers (5-CACA
CCTCTAAGAATCACAATAG-3 and 5-AATTCATGAAAATGTGTTAAA
G-3). VSG probes were generated from cloned VSG221 and VSG800 by using
primers specific for VSG221 (5-CGAGGAGCTAGACGACCAAC-3 and 5-T
CGCTGTTGCAGTAGCTGTT-3) and VSG800 (5-ATGCGGCCTAACTGA
TGAAC-3 and 5-TATCTTTGTAGGCCGCTGCT-3).
Pulsed-field gel electrophoresis and Southern blot analysis. Chromosome
separation was performed by contour-clamped homogenous electric field
(CHEF) electrophoresis with a Bio-Rad CHEF-DR II system (Bio-Rad, Hercu-
les, CA). Genomic plugs were prepared by immobilizing trypanosomes at a
concentration of 2 107 cells per 1 ml in 0.7% low-melting-temperature agarose.
The plugs were poured, allowed to solidify at 4°C, and then treated with pro-
teinase K (1 mg/ml) for 48 h before use. Agarose gels were prepared in 1 TAFE
(0.01 M Tris, 0.5 mM Titriplex II EDTA, 0.025% acetic acid) and were electro-
phoresed at 12°C with buffer recirculation. Hansenula wingei (Bio-Rad) chromo-
somes were run concurrently as a standard. The switch time was fixed at 900 s.
The overall running time was 72 h at 2.0 V/cm, and the included angle was 120°
in 1 TAFE. Radiolabeled probes for VSG221 and VSG800 for Southern blot-
ting were prepared as described above. The GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase) gene was used as a control probe for trypanosome chro-
mosome VIa (34).
SAGE. Serial analysis of gene expression (SAGE) libraries were constructed
using 30 g total RNA, purified as described above and DNase treated, from
T. b. brucei 427-221 and 427-800 populations following the I-SAGE Long kit
protocol (Invitrogen, Carlsbad, CA). Recombinant pZEro1 clones produced by
SAGE were purified using GeneMachines RevPrep Orbit (Genomic Solutions,
Ann Arbor, MI) and were sequenced on an ABI 3730xl DNA sequencer (Ap-
plied Biosystems, Foster City, CA). Sequences collected were analyzed with
software created at the MBL specifically for T. b. brucei SAGE analysis. The
SAGE software extracts ditag sequences from the ABI 3730xl results according
to the SAGE sequence grammar, parses out individual SAGE tags, excludes tags
with sequence ambiguities, and reduces all SAGE tags to a look-up table of
unique SAGE tag sequences and their observed frequencies among all of the T.
b. brucei SAGE libraries. SAGE tags not found more than once in at least one
SAGE library were excluded from analyses as putative sequencing error, unless
the tag sequence had a perfect match to available T. b. brucei genomic data. The
unique tag sequences were mapped to all available T. b. brucei DNA sequences
to determine the identities of expressed genes. For this, draft assembly contigs
and open reading frame (ORF) calls from the TIGR and Sanger sequencing
centers were downloaded from their respective FTP sites and supplemented with
nonredundant T. b. brucei genome sequences available at NCBI (113 total con-
tigs summing to 25,496,703 bp with 9,737 total predicted ORFs). The 21-bp
SAGE tags were mapped to assembly contigs based on exact sequence matches.
Tags were then visualized in a generic model organism database using the
Gbrowse interface (61) in the context of genome sequences and predicted open
reading frames. As SAGE tags are generated from the most 3 NlaIII restriction
site of transcripts, tags with significant differential expression among the SAGE
libraries were manually assigned to predicted genes based on their position
relative to predicted ORFs. These genes were annotated by BLAST and other
homology detection methods. SAGE tags were scored for differential expression
among the 427-221 and 427-800 libraries by use of the Stekel et al. (62) R
statistic, a log likelihood ratio statistic which scores tags by their deviation from
the null hypothesis of equal frequencies given the tag sampling depth for each
SAGE library. Higher scores represent a greater deviation from the null hypoth-
esis, while scores close to zero represent near-constitutive expression. To reduce
the effects of sampling error in highlighting differential expression, only tags with
an R value of 4 or greater were considered for RT-PCR and other post-SAGE
analysis.
RESULTS
In vitro generation of HDL-resistant T. b. brucei. In the
initial round of selection for HDL-resistant T. b. brucei, cells
were treated with low concentrations of human HDL (Table 1).
Cultures exposed to concentrations of HDL above 0.03% (0.5,
1.0, 1.5, and 2.0 l) failed to yield viable cells. Trypanosomes
that survived the initial round of selection (427-0.1) were ex-
panded and a second round of human HDL selection started.
During each round of selection, the population of cells able to
grow at the highest HDL concentration was expanded and
FIG. 1. T. b. brucei 427-800 cells are resistant to human HDLs. The
percentages of trypanosomes lysed following incubation for 4 h at 37°C
with designated trypanolytic units of human HDLs are shown. A unit
of HDL is defined as the amount of HDL needed to lyse 50% of 1 
107 trypanosomes during a 2-h incubation at 37°C. T. b. brucei 427-221
(blue circles), 427-12 (black inverted triangles), 427-20 (black squares)
and 427-800 (red triangles) and T. b. rhodesiense (KETRI 2482) (green
diamonds) were analyzed.
TABLE 1. In vitro selection for human HDL-resistant T. b. brucei
Amt(s) human HDL (l)/wella Populationdesignation
0......................................................................................................427-221
0, 0.1, 0.5, 1, 1.5, 2 .......................................................................427-0.1
0, 0.1, 0.5, 1, 1.5, 2 .......................................................................427-0.5
0, 0.5, 1, 1.5, 2, 2.5 .......................................................................427-1
0, 1, 3, 5, 7, 10 ..............................................................................427-3
0, 5, 10, 12, 15, 20 ........................................................................427-12
0, 12, 15, 20, 25, 30 ......................................................................427-20
0, 15, 30, 60, 190, 120 ..................................................................427-60
0, 60, 100, 200, 300, 400 ..............................................................427-300
0, 300, 500, 700, 800, 1,000 .........................................................427-800
a Shown are the amounts of human HDL added to each well in a 3-ml culture
of T. b. brucei 427-221 for 24 h. The highest concentration of HDL that yielded
viable cells during a round of selection is indicated in bold. These cells were
allowed to recover for 5 to 14 days and then were used in the next round of
selection.
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treated with increasing amounts of human HDL. Following
eight rounds of selection over a 9-month period of time, a
population of T. b. brucei resistant to 800 l of human HDL
added to growth media was obtained. The 427-800 cell line is
highly resistant not only to human HDL but also to purified
TLF and is able to grow in the presence of 25% normal human
serum (data not shown).
To determine whether the observed HDL resistance was a
stable trait, trypanosome populations and clonal lines of each
were expanded and tested for susceptibility to lysis by human
HDLs (Fig. 1). Trypanosome populations selected with in-
creasing concentrations of human HDLs were resistant to hu-
man HDLs at concentrations corresponding to those used in
the selection protocols. Both the 427-12 and 427-20 popula-
tions were intermediate in susceptibility to human HDL killing
compared to the T. b. brucei 427-221 population and the highly
resistant T. b. brucei 427-800 and T. b. rhodesiense populations
(Fig. 1).
Uptake and localization of TLF. The uptake and localization
of TLF may contribute to the resistance of T. b. rhodesiense to
normal human serum killing (22). To investigate TLF uptake
by T. b. brucei 427-800, TLF was conjugated with Alexa-488
and incubated with both 427-221 and 427-800 cells (Fig. 2). T.
b. brucei 427-221 rapidly endocytosed the labeled TLF. Intra-
cellular, fluorescent granules were initially visible within 30
min and accumulated during the 1.5-h incubation at 37°C (Fig.
2A, C, D, and E). In contrast, T. b. brucei 427-800 cells failed
to take up TLF (Fig. 2B, F, G, and H). We had shown previ-
ously that treatment of T. b. brucei with low concentrations of
chloroquine (50 M) inhibited acidification of the lysosome,
ablated TLF killing, and resulted in the accumulation of TLF
in the lysosome (21, 58). Therefore, even low levels of TLF
uptake would be detectable under these conditions, since it
would accumulate in the lysosome of the chloroquine-treated
cells. When T. b. brucei 427-221 cells were preincubated with
chloroquine, Alexa-conjugated TLF levels were elevated rela-
tive to cells not treated with chloroquine. Consistent with
previous results, the Alexa-conjugated TLF colocalized with
the lysosomal protein p67 in the T. b. brucei 427-221 cells
(Fig. 3) (21, 58). No TLF uptake or accumulation was de-
tected in the T. b. brucei 427-800 cells. These results contrast
our findings for T. b. rhodesiense, where TLF was taken up
by human HDL-resistant trypanosomes but failed to localize
to the lysosome (22).
Identification of expressed VSGs. Since T. b. brucei 427 lacks
the SRA gene, we took an unbiased approach to look for
differences in the 427-221 and 427-800 trypanosomes that
might explain the HDL resistance trait. When total cell protein
FIG. 2. T. b. brucei 427-800 does not take up TLF. Cells were
preincubated with chloroquine for 30 min and then exposed to Alexa-
labeled TLF (green) for 1.5 h at 37°C. Panels A, C, D, and E show T.
b. brucei 427-221 cells. Panels B, F, G, and H show T. b. brucei 427-800
cells. Panels A, B, E, and H are merged phase-contrast and Alexa-488
images. Panel C and F are phase-contrast images only, and panels D
and G are Alexa-488 images only.
FIG. 3. Lysosomal localization of TLF in T. b. brucei 427-221. T. b.
brucei 427-221 and 427-800 were preincubated with chloroquine for 30
min and then exposed to Alexa-488-labeled TLF (green) for 1.5 h at
37°C. Cells were then fixed with methanol and incubated with anti-
bodies to the lysosomal protein p67 (red). DAPI (blue) staining was
used to localize the nucleus (n) and kinetoplast (k).
FIG. 4. Changes in proteins expressed in HDL-selected T. b. brucei
427. (A) Coomassie-stained SDS-polyacrylamide gels of total cell pro-
tein from T. b. brucei 427-221, 427-1, 427-3, 427-12, 427-20, and 427-
800. A prominent protein corresponding to the expressed VSG is
indicated with an arrowhead: red, VSG221; green, VSGV02; and blue,
VSG800 (GenBank accession no. DQ667685). Sizes in kilodaltons are
given at right. (B) Western blot analysis of protein sample with anti-
VSG221. (C and D) Immunofluorescence analysis of 427-221, 427-3,
427-12, and 427-800 cells stained with DAPI (C) and anti-VSG221 (D).
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from the 427-221, 427-1, 427-3, 427-12, 427-20, and 427-800
populations was fractionated on SDS-polyacrylamide gels,
changes in the overall protein banding patterns were observed
(Fig. 4A). A major protein migrating at approximately 50 kDa
(Fig. 4A) in the 427-221, 427-1, and 427-3 cells was absent in
the 427-12, 427-20, and 427-800 cells. A new protein migrating
at approximately 62 kDa was present in the 427-12 and 427-20
cells, while a protein migrating at approximately 55 kDa was
present in the 427-800 cells (Fig. 4A). As we will show later,
these differences correspond to changes in VSG expression.
Western blotting and immunofluorescence microscopy con-
firmed that the 427-221, 427-1, and 427-3 trypanosomes
express VSG221 (Fig. 4B and D). Low levels of VSG switch-
ing were expected to occur during the course of the in vitro
selection experiment, but it was unexpected that the try-
panosomes that had switched VSGs would become the pre-
dominant cells in the resistant populations in the absence of
immune selection. This suggested that expression of a dif-
ferent VSG provided a selective survival advantage in the
presence of human HDL.
In order to determine the VSG expressed by the T. b. brucei
cell line highly resistant to human HDL, we cloned and se-
quenced the expressed VSG cDNA from 427-800 cells. The
cDNAs for the VSG expressed by the 427-221 and 427-800
cells were amplified from total cell RNA by reverse transcrip-
tase PCR with primers specific to the conserved sequence
within the 3 untranslated region of all VSG genes and the
spliced leader RNA that is trans-spliced to the 5 end of all
trypanosome mRNAs. These cDNAs were cloned and se-
quenced. The 427-221 cDNA corresponded to the expected
VSG221, while the 427-800 cDNA was unique. To verify that
the 427-800 VSG corresponded to the expressed protein, the
VSG was purified using conditions specific for the release of
glycosylphosphatidylinositol (GPI)-anchored proteins (43).
The 55-kDa protein was trypsin treated and analyzed by mass
spectroscopy. We were able to unambiguously identify the
VSG800 based on the determined mass of 20 peptides covering
roughly half of the predicted VSG800 sequence (data not shown).
The in vitro selection of human HDL-resistant 427-800 cells
raised the possibility that VSG800 might be functionally or
structurally similar to the SRA protein expressed by T. b.
rhodesiense (9). To examine this, the predicted protein se-
quences for VSG221, VSG800, and SRA were aligned using
the computer program MUSCLE (14) (Fig. 5). As reported by
FIG. 5. Alignment of the predicted amino acid sequences of VSG221, VSG800, and SRA, produced using the computer program MUSCLE
(14), with manual correction by eye. Predicted signal sequences are indicated in blue, predicted alpha-helical regions are underlined, and putative
GPI anchor sites are shown in red. Numbers on the right indicate amino acids.
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others, SRA contains a large internal deletion relative to other
known VSG genes (8). Overall, VSG and SRA sequences show
limited sequence similarity outside of the conserved C-termi-
nal portion of the proteins. However, SRA and VSGs do share
several structural and functional features, including an N-ter-
minal signal sequence, a C-terminal GPI anchor site, and ex-
tended regions of predicted -helices (Fig. 5). Comparison of
SRA with VSG221 and VSG800 did not suggest that VSG800
had greater homology to SRA than other VSGs.
Based on the cDNA sequences of SRA, VSG221, and
VSG800, specific primers were designed to determine whether
these genes were present in the 427-221 and 427-800 cell lines
as well as the KETRI 2482 line of T. b. rhodesiense (Fig. 6A).
The VSG221 and VSG800 genes were detected in T. b. brucei
427-221 genomic DNA, but the VSG221 gene was absent from
T. b. brucei 427-800. This is consistent with studies from other
labs that have reported that the VSG221 gene is single copy
and that gene conversion within the 221ES could lead to loss of
the VSG221 gene (53). PCR amplification of genomic DNA
failed to detect a copy of the SRA gene in either T. b. brucei
427-221 or T. b. brucei 427-800. However, the SRA gene was
readily amplified from total genomic DNA from T. b. rhodesiense
(KETRI 2482) (Fig. 6A).
The expression of VSG221 and VSG800 was confirmed by
Northern blot hybridization with cDNA probes and total RNA
from T. b. brucei 427-221 and 427-800, respectively (Fig. 6B).
The SRA mRNA was detected in the T. b. rhodesiense total
mRNA but not in RNA samples from either of the T. b. brucei
cell lines (Fig. 6B). These findings show that our in vitro-
generated, human HDL-resistant T. b. brucei line does not
express SRA and that acquisition of HDL resistance correlates
with VSG switching.
Transcriptome analysis by SAGE. SAGE offers a powerful,
unbiased approach for the analysis of genome-wide mRNA
abundance differences in different cell populations. After the
removal of putative sequencing error, a total of 38,545 and
38,334 SAGE tags (21 bp each) were sampled from 427-221
and 427-800, respectively. The sampled tags represented 26,385
unique 21-bp sequences, of which roughly 85% mapped to a
single location in the genome. The SAGE analysis revealed
that a major difference between the 427-221 and 427-800 tran-
scriptomes was the presence of VSG221 and VSG800 tran-
scripts in the respective cell lines (Table 2). We also found that
SAGE tags specific for ESAG1, ESAG2, the terminal ESAG3,
and ESAG8b encoded in the 221ES were absent in 427-800.
Other, differentially abundant tags corresponded to transcripts
for housekeeping proteins including tubulin, translation elon-
gation factors, ribosomal proteins, and enolase. These were
present in both the 427-221 and 427-800 libraries and may
FIG. 6. Analysis of the VSG221, VSG800, and SRA genes and tran-
scripts in T. b. brucei and T. b. rhodesiense. (A) PCR analysis of
genomic DNA from T. b. brucei 427-221 (lane 1) and 427-800 (lane 2)
and T. b. rhodesiense (lane 3) for VSG221, VSG800, and SRA genes.
The VSG221 gene is deleted in the T. b. brucei 427-800 line, and the
SRA gene is present only in T. b. rhodesiense. (B) Northern blot anal-
ysis of VSG221, VSG800, and SRA expression in T. b. brucei 427-221
(lane 1), 427-800 (lane 2), and T. b. rhodesiense (lane 3).
TABLE 2. Differences in mRNA abundance between T. b. brucei 427-221 and 427-800, as detected by SAGEa
Tag ID no.b Tag sequence Annotationc
Frequency in:
R valued Fold change427-221
library
427-800
library
43548 CATGGCAGATGGCGGCTGACA vsg800 primary tag 0 513 155.44 P/Ae
21744 CATGGACTGCTAAAGAAGGTC vsg800 secondary tag 0 68 20.60 P/A
22017 CATGGGCGGTTACCTATCTTT vsg800 secondary tag 0 15 4.54 P/A
43207 CATGCAAATGGCATAACGATG vsg221 primary tag 447 0 133.68 P/A
26 CATGATGGACACCAGCGGAAC vsg221 secondary tag 67 0 20.04 P/A
56 CATGTGAGGGAGAACTAAAAA esag1 44 0 13.16 P/A
177 CATGAAAATCCTGAGGCAGAA esag3 f 20 0 5.98 P/A
263 CATGTGCACTGGACTATGAGC esag8b 15 0 4.49 P/A
615 CATGTCTTTTATTCTACTTTC Putative 40S ribosomal protein S23 7 33 4.04 4.74
43734 CATGGTCAGATGCATCACTGC Elongation factor 2 36 110 8.68 3.07
43193 CATGGATACGAAGGTAAGCCC Enolase 30 84 5.89 2.82
42626 CATGCTCAGGGACTAAAAAAA Unresolved SAGE tag 25 67 4.40 2.69
41477 CATGGTTGCATAACTGTATGC Putative 40S ribosomal protein S13 27 69 4.21 2.57
42586 CATGATAAAATATTTGTGGGT Elongation factor 1 alpha 78 167 7.36 2.15
43126 CATGATGTGGGATGTATTGGG Beta tubulin 142 266 8.56 1.88
a Tags are sorted by change (n-fold), which has been calculated with correction for total sampling effort. Data presented in bold represent tags from the 221ES.
b ID, identification.
c Primary tags are those from the most 3-proximal NlaIII site of transcripts, whereas secondary tags are produced for highly abundant transcripts by incomplete
NlaIII digestion during SAGE library construction.
d SAGE is performed without replicates upon a single RNA extract, making traditional statistics unworkable. As such, SAGE is best viewed as a measure of relative
change. To reduce the effects of sampling and sequencing error in highlighting differential expression, only tags with log likelihood (R) values of 4 or greater are shown.
Higher log likelihood scores represent a greater deviation from the null hypothesis of equal abundance among the two SAGE libraries.
e Tags completely absent in either the 427-221 or 427-800 library are presented as P/A (present/absent).
f Two copies of esag3 exist in the 221ES. SAGE tag no. 177 maps to the terminal copy only.
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reflect differences in cell density at the time when RNA was
extracted for SAGE library construction. These results showed
that selection for HDL resistance accompanied VSG switching
and possible loss of ESAG1, ESAG2, the terminal copy of
ESAG3, and ESAG8b expression from the 221ES.
Expression site characterization. Since VSG switching may
occur by either gene conversion or activation of a new, previ-
ously silent expression site, we examined the chromosomal
location of VSG800 in T. b. brucei 427-221 and 427-800 (Fig. 7).
CHEF blotting confirmed loss of VSG221 and duplication of
VSG800 in the 427-800 cell line. The new copy of VSG800
localized to chromosome VIa, which contains the 221ES. Each
chromosome, however, contains two ES. It was therefore neces-
sary to directly determine whether the 221ES was transcribed in
the 427-800 cell line. The ESAG6/7 genes of T. b. brucei have
been extensively characterized, and their sequences are diag-
nostic for the different bloodstream expression sites. cDNA
clones were prepared for a hypervariable region of ESAG6/7
from 427-800 (data not shown). The sequence of these clones
was identical to that of the 221ES copy of ESAG6/7.
To better evaluate the transcribed ES in T. b. brucei 427-800,
we reexamined the SAGE tags of the 427-221 and 427-800 cell
lines (Table 3). Both cell lines contained similar numbers of
SAGE tags throughout the ES, from ESAG6/7 to ESAG8b
(Fig. 8A). Starting at ESAG8b, three 221ES-specific SAGE
tags (no. 263, no. 177, and no. 56) were observed only in the
427-221 cells, suggesting the duplicated VSG800 recombined at
or near ESAG8b. RT-PCR analysis of RNA from 427-221 and
427-800 cells revealed the presence of ESAG1, -2, -3, and -8
transcripts in both cell lines but suggested that the levels of
ESAG1 and -2 in the 427-800 cells were reduced while ESAG3
and ESAG8 transcript levels remained largely unchanged (Fig.
8B). To determine whether the transcripts amplified in these
reactions came from the 221ES, we prepared and sequenced
cDNAs from 427-800 and 427-221 cells by using ESAG1-,
ESAG2-, ESAG3-, and ESAG8-specific primers. Comparison
of the cDNAs indicated that the 427-800-derived transcripts
were distinct from the 221ES-encoded ESAG1 and -2 tran-
scripts (Fig. 8C). We sequenced three ESAG1, seven ESAG2,
and 113 ESAG3 cDNA clones from the 427-800 cells. No
sequences identical to that of the 221ES ESAG1 were identi-
fied in the 427-800 cDNA clones. However, we did identify one
ESAG1-like sequence with 97% nucleotide similarity to the
221ES ESAG1 sequence. A second cDNA had extensive sim-
ilarity to small regions of the 221ES ESAG1 but only 7%
overall similarity (Fig. 8C). We also did not find cDNAs with
sequences identical to that of the 221ES ESAG2 in the 427-800
cell line. However, we did identify two ESAG2-like sequences
with 97% and 93% nucleotide similarity to the 221ES ESAG2
sequence (Fig. 8C). The analysis of ESAG3 expression is com-
plicated by the presence of three copies of ESAG3 in the
FIG. 7. Analysis of chromosomal locations of VSG221 and VSG800
by CHEF and Southern blotting. (A) Ethidium bromide-stained
CHEF gel of total genomic DNA from T. b. brucei 427-221 and 427-
800. H. wingei chromosomes were used as markers (M). (B) Southern
blot of genomic DNA from T. b. brucei 427-221 and 427-800 probed for
VSG221. The VSG221 gene is absent in the T. b. brucei 427-800 ge-
nome. (C) Southern blot of genomic DNA from T. b. brucei 427-221
and 427-800 probed for VSG800. One copy of the VSG800 gene is
present in both populations, while a second copy is present only in T.
b. brucei 427-800 and localizes to chromosome VIa, which contains the
221ES.
TABLE 3. Mapping of SAGE tags to the 221ESa
Tag ID no.b Tag sequence Annotation
Frequency in:
R value427-221
library
427-800
library
41524 CATGTGGTATGTACAAGCTAC esag6/7c 44 25 1.13
41878 CATGGGGAACACTGCTGTGCT esag6 32 32 0.00
43692 CATGTAAGGAAACGGCAACAG Downstream of esag6 58 45 0.34
63 CATGATATAAAACGTGGATGC esag5 40 45 0.07
87 CATGAAAATCCTGGGGCAGCA esag3/3d 34 28 0.12
42811 CATGTGGGGAGGGGTGACTTT esag4 46 38 0.16
42492 CATGATCTTTTTTTTCTGATT Hypothetical protein H25N7.21 38 39 0.00
501 CATGGAATTGATGTCTCTTCC esag8/8be 10 2 1.25
41933 CATGTGCCTTGTGCTTCTTTT Hypothetical protein H25N7.25 15 2 2.43
263 CATGTGCACTGGACTATGAGC esag8b 15 0 4.50
177 CATGAAAATCCTGAGGCAGAA esag3 20 0 6.00
56 CATGTGAGGGAGAACTAAAAA esag1 44 0 13.16
a Tags are approximately sorted by position on the 221ES (GenBank accession no. AL671259) (Fig. 8). Data presented in bold represent tags with sequences entirely
unique to the 221ES. All other tag sequences can be mapped to other known T. b. brucei expression sites but not non-ES locations.
b ID, identification.
c Tag no. 41524 cannot discriminate between esag6 and esag7 transcripts.
d Tag no. 87 maps to both the esag3 pseudogene and the functional esag3 copy in the middle of the ES. It does not map to the terminal copy of esag3.
e Tag no. 501 maps to both copies of esag8 as well as to esag8b. As tag no. 263 independently suggests an absence of esag8b transcripts in 427-800, we assume esag8b
does not contribute to the frequency of tag no. 501 in 427-800.
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221ES. Within the 221ES is an upstream ESAG3 pseudogene
(ESAG3) and two nearly identical copies of ESAG3. We des-
ignated these copies ESAG3 (for the upstream copy of the gene)
and ESAG3b (for the downstream copy) (Fig. 8A). As expected
from the SAGE analysis, we identified cDNAs for ESAG3, -3b
and -3 in 421-221 cells (Fig. 8C). While SAGE detected the
possible presence of ESAG3 transcripts in 427-800 cells, we could
detect transcripts only from ESAG3 and a non-221ES copy of
an ESAG3-like transcript by RT-PCR. While RT-PCR analysis of
ESAG8 revealed the two products expected for ESAG8 and -8b,
sequencing failed to resolve whether one or both copies of
ESAG8 were expressed (data not shown).
FIG. 8. Mapping of SAGE tags from T. b. brucei 427-221 and 427-800 to the 221ES (GenBank accession no. AL671259) and analysis of ESAG1,
-2, and -3 expression. (A) Mapping of SAGE tags to the 221ES. Included on the map are ESAG, VSGs, and their pseudogenes present before
(427-221) and after (427-800) recombination. SAGE tags mapping to more than one location on the 221ES are underlined. SAGE tag identification
numbers and frequencies can be found in Tables 2 and 3. Tags unique to 427-221 (red) and 427-800 (blue) are indicated. (B) Analysis of transcripts
from 221ES genes from 427-221 and 427-800. RT-PCR products were prepared using the specific primer pairs described in Material and Methods
and were fractionated by agarose gel electrophoresis and stained with ethidium bromide. (C) Sequence analysis of ESAG1, -2, and -3 cDNAs from
427-221 and 427-800 cells. Only a portion of the derived cDNA sequence is shown for each of the cDNA clones. A single ESAG1 transcript was
present in the 427-221 cells, and its sequence was identical to that of the ESAG1 in the 221ES. In contrast, two ESAG1-like sequences not present
in the 221ES were obtained from the 427-800 cDNA clones. For ESAG2, a single transcript was expressed in the 427-221 cells and its sequence
was identical to the ESAG2 sequence in the 221ES. In contrast, two ESAG2-like sequences not found in the 221ES were obtained from the 427-800
cDNA clones. Transcripts from the 221ES ESAG3	, -3, and -3b were present in the 427-221 cells. ESAG3	 transcripts were also present in the
427-800 cells, in addition to an ESAG3-like transcript not encoded by the 221ES.
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Based on the combination of SAGE analysis and cDNA
sequence analysis, we conclude that the duplication and trans-
position of VSG800 into the 221ES resulted in deletion of
coding sequences for ESAG1, -2, and -3b. The transcripts in
the 427-800 cells are the result of transcription of related genes
from other copies in the 221ES, other expression sites, or
internal chromosomal copies. We are currently preparing telo-
mere clones of the 221ES from 427-800 cells to precisely define
the ESAGs deleted during the transposition of VSG800 into
the 221ES.
DISCUSSION
The resistance of humans to infection by T. b. brucei is a
consequence of an innate, protective class of human HDLs
containing apoL-1, Hpr, apoA-1, and apoA-II (23, 50, 57, 59,
60, 65, 69). African trypanosomes that cause human sleeping
sickness circumvent the cytotoxic activity of this HDL subclass.
The infectivity of T. b. rhodesiense for humans requires the
expression of the VSG-like protein, SRA, which localizes to
intracellular organelles of the endocytic pathway and the lyso-
some (9, 35, 41, 69, 74). While the mechanism of TLF inhi-
bition by SRA is not completely understood, recent studies
suggest that binding of SRA to apoL-1 neutralizes the trypano-
some-killing activity of TLF (69). Both the SRA gene and its
telomeric ES are highly conserved in T. b. rhodesiense (16).
This has led to the suggestion that the SRA gene arose only
once during evolution and subsequently spread through ge-
netic exchange (17, 18).
Although compelling evidence supports the role of SRA in
human infectivity by T. b. rhodesiense, several investigators
have reported the occurrence of human serum-resistant lines
of African trypanosomes that lack the SRA gene (2, 47, 66, 67).
To investigate the mechanism of SRA-independent resistance,
we generated human serum-resistant lines of T. b. brucei 427
(MiTat 1.2) by repeated in vitro exposure to human HDLs. We
extensively characterized one human HDL-resistant line, T. b.
brucei 427-800, which was also highly resistant to purified TLF
and could grow in media containing 25% normal human se-
rum. The resistance phenotype correlated with the absence of
TLF binding and accumulation in T. b. brucei 427-800 cells
(Fig. 2 and 3). Analysis of both protein and RNA profiles
indicated that T. b. brucei 427-800 continued to transcribe the
221ES, but ESAG1, -2, -3, and -8b mRNAs (from the 221ES)
were not detected and VSG800 was transcribed (Fig. 8; Table
3). Duplication and transposition of VSG800 into the 221ES
were confirmed by CHEF blotting (Fig. 7). These studies show
that human HDL-resistant variants of T. b. brucei 427 can be
generated in vitro and that the resistance phenotype is directly
linked to antigenic variation. Based on these findings, we pro-
pose that resistance to human HDLs is due to either the
expression of VSG800, the deletion of ESAG1, -2, -3, or -8b
from the 221ES, or some other unknown mechanism.
The potential for antigenic variation to directly influence
human serum susceptibility or resistance was previously pro-
posed based on studies of T. b. rhodesiense and T. b. gambiense
isolates that had lost human serum resistance following VSG
switching (25, 42, 74). Based on the genomic organization of
the SRA gene within bloodstream expression sites, it is possible
that antigenic switching by in situ activation of a new, SRA-
lacking ES is the mechanism of loss of human serum resistance
in T. b. rhodesiense (74).
By analogy to the role that SRA acts as an inhibitor of
human HDL killing of T. b. rhodesiense, one might expect
human HDL-resistant T. b. brucei 427-800 to express a protein
that specifically interacts with TLF and ablates its activity.
Since SRA is a member of the VSG family of proteins, it is
possible that in vitro exposure of T. b. brucei to human HDL
may have selected for the expression of a VSG that conferred
resistance. The T. b. brucei genome contains a large number of
silent VSG genes, many of which are clustered at internal
locations on large chromosomes, with a minority of these genes
distributed at telomeres of minichromosomes, intermediate
chromosomes, and megabase chromosomes. The expression of
VSG genes is tightly regulated to ensure that a single telo-
meric VSG is transcribed at a time. This leaves hundreds of
silent VSG genes free of functional constraints and susceptible
to random sequence drift contributing to the variability of
VSGs. The high multiplicity of silent VSG genes provides a
potential pool for selection of a gene that could confer resis-
tance to human HDLs. Based on limited sequence comparison,
we have been unable to identify features of VSG800 that might
contribute to inhibition of human HDL killing of trypano-
somes. However, the role of VSG800 in the resistance trait can
be evaluated directly by replacement of the VSG221 gene in
the human HDL-susceptible T. b. brucei 427-221 cell line. This
experiment is under way.
In addition to SRA, there is at least one other example of
a VSG that has evolved to take on a different function. The
trypanosome Tf-Rs are encoded by ESAG6 and ESAG7 and
assemble as a heterodimeric receptor anchored to the flagellar
pocket by a single GPI on the ESAG6-encoded subunit (6, 27,
54, 63). The ESAG6 and ESAG7 subunits contain VSG-like
N-terminal domains that facilitate packing within the VSG
surface coat in the flagellar pocket and variable C-terminal
sequences with differing affinities for mammalian transferrins
(55). Growth of trypanosomes in different sera can select for
VSG ES switching and results in the expression of different
Tf-Rs (5, 15). A correlation to the relative transferrin binding
affinity of the expressed trypanosome Tf-R and the host trans-
ferrin has been made previously (15, 71).
T. b. brucei 427-800 and T. b. rhodesiense clearly share the
human HDL resistance phenotype in a standard lysis assay.
Despite this superficial similarity, analysis of TLF uptake and
localization revealed differences. Two reports show that TLF
(22) or purified apoL-I (69) is taken up by T. b. rhodesiense. In
a study with native purified TLF we have found that, although
TLF accumulation was reduced in T. b. rhodesiense, flagellar
pocket binding and perhaps endocytosis occurred. However,
TLF did not traffic to the lysosome (22). Vanhamme and co-
workers also found that T. b. rhodesiense bound recombinant
apoL-I but, in contrast to our initial studies, found that apoL-I
was efficiently taken up and colocalized to the trypanosome
lysosome with SRA (69). In the studies reported here, we were
unable to detect TLF accumulation in T. b. brucei 427-800 cells,
raising the possibility that human HDL resistance in T. b.
brucei 427-800 may result from loss of the TLF receptor. Con-
sistent with this possibility, we found that ESAG1, -2, and -3
were potentially deleted during the transposition of VSG800
into the 221ES and that transcripts from these genes were
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absent in the SAGE library and also in cDNAs prepared from
T. b. brucei 427-800 (Table 3; Fig. 8). ESAG1 and -2 are
interesting candidates for the TLF receptor in T. b. brucei.
ESAG2 is a GPI-anchored protein found exclusively in the
flagellar pocket of bloodstream trypanosomes (40, 44). Less is
known about ESAG1, but it is predicted to be a transmem-
brane cell surface protein in bloodstream trypanosomes (44).
While the function of each of these proteins is unknown, it is
interesting to note that another human serum-resistant line of
T. b. brucei (TREU 927; GuTat 10.1) also lacks these genes in
the active expression site (66, 67).
We have shown here that T. b. brucei can gain serum resis-
tance after repeated exposure to human HDL. The genetic
cause of resistance has not been thoroughly determined; we
have shown, however, that the lack of TLF accumulation in the
lysosome is the most likely cellular mechanism. This phenotype
may be due to the expression of VSG800, which, by some
unknown mechanism, inhibits uptake of TLF. Alternatively,
TLF resistance might be a consequence of loss of a gene
encoding the TLF receptor during recombination of VSG800
into the 221ES. These possibilities are currently being tested.
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